<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802697</url>
  </required_header>
  <id_info>
    <org_study_id>11-HMedIdeS-01</org_study_id>
    <secondary_id>2012-000969-21</secondary_id>
    <nct_id>NCT01802697</nct_id>
  </id_info>
  <brief_title>Safety Study on IdeS in Healthy Volounteers</brief_title>
  <official_title>A Phase i Single Center Study to Evalute the Safety, Tolerability and Pharmacokinetics of Intravenous IdeS After Administration of Single Ascending Doses in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hansa Medical AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hansa Medical AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in man study to assess safety and tolerability of the IgG cleaving enzyme
      Immunoglobuli G degrading enzyme of streptococcus pyogenes (IdeS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I study (11-HMedIdeS-01, EudraCT no. 2012-000 969-21) first in man single ascending
      dose study in 29 healthy subjects to investigate if IdeS is safe and well tolerated in doses
      up to 0.24 mg/kg body weight (BW).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by adverse events</measure>
    <time_frame>64 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration of IdeS</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Total IgG concentration</measure>
    <time_frame>64 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IdeS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBS Buffer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IdeS</intervention_name>
    <arm_group_label>IdeS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>PBS Buffer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and sign informed consent

          -  BMI 19-30

        Exclusion Criteria:

          -  Clinically significant disease

          -  Positive HIV, hepatistis B or C

               -  Drug abuse

          -  Smoking

          -  Use of medication except paracetamol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Malmqvist, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trial Unit, SUS, Lund, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Unit, FoU centrum Skåne, Skåne University hospital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

